Rise Therapeutics Secures New Funding To Advance First-in-Class R-2487 Oral Immune Biomodulator Into Sjogren’s Disease Clinical Testing (Bio Space)
UF startup Rise Therapeutics, a clinical-stage biotechnology company developing a novel class of oral targeted immunotherapies, announced it will be initiating clinical evaluation of R-2487 in SjD.